Abstract: The present disclosure relates to a system and method capable of capturing, processing and analyzing electroencephalography (EEG) signals to deliver or support an expert interpreter in delivering a clinically-relevant interpretation for patients with Alzheimer's disease. Such interpretations include identification of diagnostic, prognostic or risk stratification neurobiomarkers to evaluate subjects for suitability in clinical trials, monitor for clinical conditions, detect adverse effects of interventions, identify efficacy of interventions or identify subjects that are more or less likely to respond to therapeutic interventions in a specified manner.

Abstract: Systems and methods for monitoring a subject under, or suspected to be under, the influence of one or more drugs are provided. In one aspect, a method comprises controlling one or more sensors of a monitoring device to acquire physiological signals from a subject suspected to be under the influence of one or more drugs, and assembling a set of physiological data using the acquired physiological signals. The method also includes generating, using a processor of the monitoring device, physiological markers characteristic of the influence of the one or more drugs by analyzing the set of physiological data, and correlating the physiological markers with a drug profile characterizing the one or more drugs affecting the subject. The method further includes proving to a user a report indicating the drug profile characterizing the one or more drugs affecting the subject.

Abstract: The present invention relates to a method of treating cognitive impairment in a patient in need thereof by administering Compound (I), a stimulator of soluble guanylate cyclase (sGC) at certain dosages either alone or in combination therapy.

Abstract: The present disclosure relates to a system and method capable of capturing, processing and analyzing electroencephalography (EEG) signals to deliver or support an expert interpreter in delivering a clinically relevant interpretation. Such interpretations include identification of diagnostic, prognostic or risk stratification neurobiomarkers to evaluate subjects for suitability in clinical trials, monitor for clinical conditions, detect adverse effects of interventions, identify efficacy of interventions or identify subjects that are more or less likely to respond to therapeutic interventions in a specified manner. The system enables actions to be performed either in real-time or asynchronously.

Abstract: Disclosed herein are methods and compositions for reversing the effects of a sedation agent or general anesthetic agents. The methods are useful for example for assessing a patient during a surgical procedure or a patient's physiologic state during and/or after a surgical procedure. Other uses for the methods and compositions include modulating a circadian rhythm, treating cardiac arrest, hypotension and bradycardia, and preventing emergence delirium.

Abstract: Systems and methods for monitoring a subject under, or suspected to be under, the influence of one or more drugs are provided. In one aspect, a method comprises controlling one or more sensors of a monitoring device to acquire physiological signals from a subject suspected to be under the influence of one or more drugs, and assembling a set of physiological data using the acquired physiological signals. The method also includes generating, using a processor of the monitoring device, physiological markers characteristic of the influence of the one or more drugs by analyzing the set of physiological data, and correlating the physiological markers with a drug profile characterizing the one or more drugs affecting the subject. The method further includes proving to a user a report indicating the drug profile characterizing the one or more drugs affecting the subject.